6.17
+3.81(+161.44%)
Currency In USD
| Previous Close | 2.36 |
| Open | 2.4 |
| Day High | 6.84 |
| Day Low | 2.4 |
| 52-Week High | 26.38 |
| 52-Week Low | 1.8 |
| Volume | 153.93M |
| Average Volume | 225,556 |
| Market Cap | 50.93M |
| PE | -2.84 |
| EPS | -2.17 |
| Moving Average 50 Days | 2.23 |
| Moving Average 200 Days | 11.08 |
| Change | 3.81 |
If you invested $1000 in CervoMed Inc. (CRVO) 10 years ago, it would be worth $0.02 as of March 13, 2025 at a share price of $6.17. Whereas If you bought $1000 worth of CervoMed Inc. (CRVO) shares 5 years ago, it would be worth $265.38 as of March 13, 2025 at a share price of $6.17.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies
GlobeNewswire Inc.
Mar 10, 2025 8:05 PM GMT
A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p<0.001 vs. old capsules; p=0.003 vs. placebo) on the primary outcome measure, change from baseline in Clinical Dementia Rating Sum of Boxe
CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference
GlobeNewswire Inc.
Jan 31, 2025 1:00 PM GMT
— Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from participants who have received capsules from a more recently manufactured batch of neflamapimod — — Pharmacokin
CervoMed to Present at the 8th International Lewy Body Dementia Conference
GlobeNewswire Inc.
Jan 29, 2025 1:00 PM GMT
BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that topline results from the Phase 2b RewinD-LB study will be p